Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mendes

Showing results (191-200 of 473) with videos related to

Pageof 48
Sort By:
Antimicrobial Agents and Chemotherapy|December 22, 2017
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical CentersHelio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2012
The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147LJacqueline LaMarre, Rodrigo E Mendes, Teresa Szal, et al.
The Journal of Antimicrobial Chemotherapy|November 3, 2014
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 21, 2016
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014)Leonard R Duncan, Helio S Sader, Robert K Flamm, et al.
Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc|August 17, 2024
Comparison of fluorescent antibody test, immunohistochemistry, and PCR testing for diagnostic confirmation of neurolisteriosis in 25 goatsDaniel R Rissi, Amy S McKinney, Jillian D Fishburn, et al.
The Journal of Antimicrobial Chemotherapy|November 20, 2025
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022-2023)Mekki F Bensaci, Karri A Bauer, Kenneth Klinker, et al.
Journal of Chemotherapy (Florence, Italy)|December 3, 2010
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infectionsM A Pfaller, P R Rhomberg, H S Sader, et al.
Diagnostic Microbiology and Infectious Disease|November 25, 2010
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum programDouglas J Biedenbach, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|July 20, 2010
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance resultsShannon D Putnam, Helio S Sader, Gary J Moet, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesDavid J Farrell, Rodrigo E Mendes, James E Ross, et al.
Pageof 48

Showing results (191-200 of 473) with videos related to

Sort By:
Pageof 48
Antimicrobial Agents and Chemotherapy|December 22, 2017
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical CentersHelio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2012
The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147LJacqueline LaMarre, Rodrigo E Mendes, Teresa Szal, et al.
The Journal of Antimicrobial Chemotherapy|November 3, 2014
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 21, 2016
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014)Leonard R Duncan, Helio S Sader, Robert K Flamm, et al.
Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc|August 17, 2024
Comparison of fluorescent antibody test, immunohistochemistry, and PCR testing for diagnostic confirmation of neurolisteriosis in 25 goatsDaniel R Rissi, Amy S McKinney, Jillian D Fishburn, et al.
The Journal of Antimicrobial Chemotherapy|November 20, 2025
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022-2023)Mekki F Bensaci, Karri A Bauer, Kenneth Klinker, et al.
Journal of Chemotherapy (Florence, Italy)|December 3, 2010
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infectionsM A Pfaller, P R Rhomberg, H S Sader, et al.
Diagnostic Microbiology and Infectious Disease|November 25, 2010
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum programDouglas J Biedenbach, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|July 20, 2010
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance resultsShannon D Putnam, Helio S Sader, Gary J Moet, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesDavid J Farrell, Rodrigo E Mendes, James E Ross, et al.
Pageof 48